Clover is one of the nine Covid-19 vaccine candidates its partner CEPI (Coalition for Epidemic Preparedness Innovations) is supporting.
Through the partnership, CEPI has provided up to US $328 million in funding to advance the development of Clover’s protein-based S-Trimer COVID-19 vaccine candidate.
The investment has supported preclinical studies and Phase I clinical trials and will now fund a global pivotal Phase 2/3 efficacy clinical trial.
It will also fund additional clinical studies in special populations, such as people with autoimmune conditions and pregnant women, and will continue to scale-up manufacturing of doses so that the vaccine is available without delay, should it be proven safe and effective in clinical testing.
The supply of Stevanato’s glass vials to Clover brings together two main pillars of CEPI’s work in COVID-19 vaccine development and manufacturing.
Photo courtesy of The Stevanato Group's LinkedIn page.